Welireg (Belzutifan)

Welireg is a hypoxia-inducible factor inhibitor used to treat adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring prompt surgery.  

Recommended Dosage: The recommended dosage is 120 mg administered orally (by mouth) once daily until the disease is progressive or unacceptable toxicity occurs. Welireg must be taken at the same time every day and may be taken with or without meal. Patients should swallow the Welireg tablets whole, without chewing, crushing, or splitting. 

If a dose is missed/skipped, it can be taken as promptly as possible on the same day. Resume the regular daily dose schedule the very next day. Do not take additional tablets to make up for the missed/skipped dose. 

In case vomiting occurs any time after taking the dosage, avoid retaking the dose. Patients should take the next scheduled dose on the very next day.

• Welireg 40 mg tablets can cause severe anemia that can require blood transfusion. Monitor for anemia prior to initiation of, and periodically throughout, therapy with Welireg. Precisely assess those who are dual UGT2B17 & CYP2C19 poor metabolizers because of potential increases in exposure that may increase the incidence or severity of anemia.
• Consideration of erythropoiesis stimulating agents (ESAs) to treat anemia is not recommended in those treated with Belzutifan. For those treated with Belzutifan who develop anemia, the safety as well as effectiveness for use of erythropoiesis stimulating agents have not been established.
• Belzutifan can cause serious hypoxia that may require interruption, supplemental oxygen, or hospitalization. Monitor oxygen saturation prior to initiation of, and periodically throughout, therapy with Belzutifan. For decreased oxygen saturation with exercise (pulse oximeter <88% or PaO2 ≤55 mm Hg), consider withholding Belzutifan until pulse oximetry with exercise is beyond 88%, then resume at the same dose or at a decreased dose.
• For reduced oxygen saturation at rest (pulse oximeter <88% or PaO2 ≤55 mm Hg) or urgent intervention indicated, withhold treatment with Belzutifan 40 mg tablets until resolved and resume at a decreased dose or discontinue. For life-threatening hypoxia or for recurrent symptomatic hypoxia, permanently discontinue treatment. Patients must report signs/symptoms of hypoxia promptly to a health specialist.
• Welireg can cause fetal harm if administered to a pregnant woman. Verify the pregnancy status of females of reproductive age prior to starting therapy with Welireg. Females of reproductive age should use apt non-hormonal contraception during therapy with Welireg and for 7 days after the final dose. This medicine can render some hormonal contraceptives ineffective. 

What documents are required to import WELIREG to India?

WELIREG (belzutifan) tablets can be imported by patients or government hospitals on the name of the patients only. 

The following documentation required to import the product:

• Valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients Identity Proof (issued by government of India)

How does order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor
• Import permit if applicable

Is WELIREG available in India?

WELIREG (belzutifan tablet) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input

• On availability of Welireg in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
• Medicine Price.
• Finding Genuine and reliable source from Canada, Europe, USA and Australia
• Ensuring 100% transparency.

WELIREG can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

IPN (Indian Pharma Network) can facilitate the supply of WELIREG (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Welireg price in India. 

We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the WELIREG (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma Network offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.